Details for Patent: 8,067,437
✉ Email this page to a colleague
Title: | Beta-2-adrenoreceptor agonists |
Abstract: | Compounds of formula ##STR00001## in free or salt or solvate form, where Ar is a group of formula ##STR00002## Y is carbon or nitrogen and R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9, R.sup.10, X, n, p, q and r are as defined in the specification, their preparation and their use as pharmaceuticals, particularly for the treatment of obstructive or inflammatory airways diseases. |
Inventor(s): | Cuenoud; Bernard (Horsham, GB), Bruce; Ian (Horsham, GB), Fairhurst; Robin A (Horsham, GB), Beattie; David (Horsham, GB) |
Assignee: | Novartis AG (Basel, CH) |
Filing Date: | Sep 20, 2010 |
Application Number: | 12/885,922 |
Claims: | 1. A method for the treatment of chronic obstructive pulmonary disease which comprises administering to a subject in need thereof an effective amount of (R)-5-[2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydro- xy-1H-quinolin-2-one in free or salt or solvate form. 2. A method according to claim 1, wherein the (R)-5-[2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quin- olin-2-one is administered in salt form. 3. A method according to claim 1, wherein the (R)-5-[2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quin- olin-2-one is administered as (R)-5-[2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quin- olin-2-one maleate. 4. A method according to claim 1, wherein the (R)-5-[2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quin- olin-2-one is administered to the subject once-a-day. 5. A method for the treatment of chronic obstructive pulmonary disease which comprises administering to a subject in need thereof a pharmaceutical composition that comprises an effective amount of (R)-5-[2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quin- olin-2-one in free or salt or solvate form together with a pharmaceutically acceptable carrier. 6. A method according to claim 1, wherein the (R)-5-[2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quin- olin-2-one is administered in salt form. 7. A method according to claim 1, wherein the (R)-5-[2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quin- olin-2-one is administered as (R)-5-[2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quin- olin-2-one maleate. 8. A method according to any claim 1, wherein the pharmaceutical composition is in inhalable form. 9. A method according to any claim 1, wherein the pharmaceutical composition is administered to the subject using an inhalation device. 10. A method according to claim 1, wherein the pharmaceutical composition is administered to the subject once-a-day. |